Abstract
Abnormalities in endothelial function, angiogenesis and thrombogenesis are found in essential hypertension. Angiotensin II has been postulated as an agent involved in these processes. We hypothesized that the treatment of essential hypertension with the angiotensin II receptor antagonist, losartan, would affect endothelial damage/dysfunction, angiogenesis and coagulation, when compared to treatment with a diuretic. Forty hypertensive patients (28 male, mean age 56 +/- 11.8 years) were randomized to treatment with losartan 50-100 mg o.d. or hydrochlorothiazide 12.5-25 mg o.d. over a 12-week period. Patients were assessed at week 0, 4 and 12. Endothelial damage/dysfunction was assessed using plasma levels of von Willebrand factor (vWf) and changes in flow-mediated dilation of the brachial artery (FMD). Vascular endothelial growth factor (VEGF) and its soluble receptor Flt-1 (sFlt-1) were measured as indices of angiogenesis, and plasma tissue factor (TF) as an index of coagulation. Baseline results in hypertensives were compared to 20 healthy controls (13 male, mean age 61.1 +/- 10.1 years). Mean patient BP was 161/95 +/- 21/18 mmHg compared to 134/81 +/- 11/7 mmHg in controls (p<0.002). Plasma levels of TF (p=0.023) were signific...Continue Reading
References
Dec 1, 1992·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·H A Struijker BoudierH van Essen
Feb 1, 1984·Diabetes·R P LambertonW J Dodds
Sep 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·H C StaryR W Wissler
Jul 1, 1994·Circulation·R T van LeeuwenG Sperti
Feb 1, 1996·Coronary Artery Disease·A D Blann, M A Waite
Jan 1, 1997·Thrombosis Research·P GalajdaP Kubisz
Mar 6, 1997·The American Journal of Cardiology·R J Cody
May 1, 1997·Clinical Cardiology·R A Vogel
May 1, 1997·American Journal of Hematology·A D BlannC N McCollum
Mar 21, 1998·Metabolism: Clinical and Experimental·I SeljeflotH Arnesen
Apr 7, 1998·Circulation·G DavìG Bittolo Bon
Apr 16, 1999·Hypertension·T F AntoniosG A MacGregor
Jul 6, 2000·The American Journal of Pathology·D N MüllerF C Luft
Jul 20, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·T HiranoM Adachi
Aug 10, 2000·American Journal of Hypertension·T K MakrisM K Kyriakidis
Nov 1, 2001·Journal of Human Hypertension·P S SeverUNKNOWN ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial
Jan 9, 2003·American Journal of Hypertension·Dirk C FelmedenGregory Y H Lip
Jun 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·David G HarrisonKathy K Griendling
Aug 14, 2003·The American Journal of Cardiology·Dirk C FelmedenGregory Y H Lip
Citations
Mar 7, 2014·PloS One·Shuang LiYawei Xu
Nov 1, 2005·Expert Opinion on Investigational Drugs·Dirk C Felmeden, Gregory Y H Lip
Jul 7, 2007·Blood Pressure·Niels H BuusKeld E Sørensen
Nov 6, 2009·Clinical and Experimental Hypertension : CHE·Hiroshi YamanariTohru Ohe
Jul 14, 2010·Clinical Biochemistry·Raffaele PalmirottaFiorella Guadagni
Nov 16, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Patrizia FerroniFiorella Guadagni
Apr 29, 2010·The Physician and Sportsmedicine·Leonardo P J Oliveira, Christine E Lawless
Feb 1, 2011·Respiratory Medicine·Vahid Mohsenin, Fred Urbano
Dec 31, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Giulia Dell'OmoRoberto Pedrinelli
Mar 14, 2007·Journal of Hypertension·Andreas J FlammerRoger Lehmann
Feb 5, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Annabella Braschi
Oct 11, 2008·The Journal of Physiological Sciences : JPS·Willmann LiangIsmail Laher
Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Jul 17, 2018·Current Medicinal Chemistry·Miroslav RadenkovićMilica Prostran
Apr 6, 2021·Frontiers in Pharmacology·Yun CaiKeji Chen